Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Oric Pharmaceuticals (ORIC) Return on Capital Employed (2020 - 2026)

Oric Pharmaceuticals filings provide 7 years of Return on Capital Employed readings, the most recent being 37.01% for Q1 2026.

  • Quarterly Return on Capital Employed rose 2386.0% to 37.01% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 37.01% through Mar 2026, up 2386.0% year-over-year, with the annual reading at 44.54% for FY2025, 1545.0% up from the prior year.
  • Return on Capital Employed hit 37.01% in Q1 2026 for Oric Pharmaceuticals, down from 35.78% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 31.11% in Q1 2022 and bottomed at 60.87% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 42.22%, with a median of 40.13% recorded in 2025.
  • The largest annual shift saw Return on Capital Employed tumbled -2100bps in 2025 before it skyrocketed 2386bps in 2026.
  • Oric Pharmaceuticals' Return on Capital Employed stood at 40.39% in 2022, then dropped by -13bps to 45.64% in 2023, then decreased by -19bps to 54.28% in 2024, then soared by 34bps to 35.78% in 2025, then decreased by -3bps to 37.01% in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Return on Capital Employed are 37.01% (Q1 2026), 35.78% (Q4 2025), and 40.13% (Q3 2025).